Cancer · 2022 · 13 citations · 14 references
MedicineHematologyPharmacologyCancer PharmacologyHematologic OncologyOncology PharmacotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyMyeloproliferative NeoplasmsBiological PrognosisChronic Myeloid Leukemia TherapyJak InhibitorsMyeloproliferative Neoplasm TherapyMyeloproliferative Neoplasm Treatment
BACKGROUND: The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) and PB ≥4% was associated with a particularly unfavorable prognosis. Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms. Its role has not been assessed in correlation with PB. METHODS: In 794 chronic-phase MF patients treated with RUX, we evaluated the impact of baseline percentage of PB on response (spleen and symptoms responses) and outcome (RUX discontinuation-free, leukemia-free, and overall survival). Three subgroups were compared: PB-0 (no PB, 61.3%), PB-4 (PB 1%-4%, 33.5%), and PB-9 (PB 5%-9%, 5.2%). RESULTS: At 3 and 6 months, spleen responses were less frequently achieved by PB-4 (P = .001) and PB-9 (P = .004) compared to PB-0 patients. RUX discontinuation-free, leukemia-free, and overall survival were also worse for PB-4 and PB-9 patients (P = .001, P = .002, and P < .001, respectively). CONCLUSIONS: Personalized approaches beyond RUX monotherapy may be useful in PB-4 and particularly in PB-9 patients.
14
Naseema Gangat, Domenica Caramazza, Rakhee Vaidya et al. · Journal of Clinical Oncology · 2010 · 1K citations · Full text
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi, T L Lasho, Paola Guglielmelli et al. · Leukemia · 2013 · 746 citations